Department of Bone and Joint Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Department of Hand Surgery, No.971 Hospital of the PLA Navy, Qingdao, China.
Pathol Res Pract. 2023 Feb;242:154329. doi: 10.1016/j.prp.2023.154329. Epub 2023 Jan 19.
Osteosarcoma (OS) is one of the most common primary bone malignancy. Combining chemotherapy and surgical treatment significantly improved clinical outcomes for osteosarcoma patients. Osteosarcoma stem cells (OSCs) are often more malignant than differentiated cancer cells and are a key determinant of responses to chemotherapy and radiation therapy, therefore, the removal of OSCs could be an effective therapeutic strategy. Myxoprotein 1 (MUC1) is aberrantly overexpressed in many human cancers and it promotes cancer stemness through activation of pluripotency networks. In this study, we observed elevated MUC1 in osteosarcoma and a depressed prognosis in patients with high MUC1 expression profiles. Our observations also revealed that MUC1 promoted OS stemness and tumor metastasis both in vivo and in vitro. These data led us to hypothesize that MUC1 may be a therapeutic target for patients with OS.
骨肉瘤（OS）是最常见的原发性骨恶性肿瘤之一。将化疗和手术治疗相结合，显著改善了骨肉瘤患者的临床预后。骨肉瘤干细胞（OSCs）通常比分化的癌细胞更具恶性，是对化疗和放疗反应的关键决定因素，因此，去除 OSCs 可能是一种有效的治疗策略。黏蛋白 1（MUC1）在许多人类癌症中过度表达，通过激活多能性网络促进癌症干性。在这项研究中，我们观察到骨肉瘤中 MUC1 升高，并且高 MUC1 表达谱的患者预后不良。我们的观察还表明，MUC1 促进了 OS 干性和肿瘤转移，无论是在体内还是体外。这些数据使我们假设 MUC1 可能是 OS 患者的治疗靶点。
